Allurion Technologies, INC. (ALURW) — SEC Filings

Q: What are the key financial highlights for Allurion Technologies, INC.?

Key financial highlights for Allurion Technologies, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Allurion Technologies, INC.?

Key executives at Allurion Technologies, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Allurion Technologies, INC. stock?

Risk factors for Allurion Technologies, INC. (ALURW) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Allurion Technologies, INC.?

Forward-looking statements and predictions from Allurion Technologies, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Allurion Technologies, INC.. Recent 8-K filing on Dec 19, 2025. AI-decoded analysis of earnings, risk factors, and insider trades.

View Allurion Technologies, INC. on SEC EDGAR

Overview

Allurion Technologies, INC. (ALURW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a DEFA14A filed on Nov 25, 2025: Allurion Technologies, Inc. filed a Definitive Additional Materials proxy statement on November 25, 2025. This filing supplements previous proxy materials and is related to the company's annual meeting. The company is incorporated in Delaware and its fiscal year ends on December 31.

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 5 bearish, 45 neutral. The dominant filing sentiment for Allurion Technologies, INC. is neutral.

Filing Type Overview

Allurion Technologies, INC. (ALURW) has filed 28 8-K, 1 DEFA14A, 3 DEF 14A, 4 10-Q, 2 10-K/A, 1 10-K, 4 S-1/A, 2 S-1, 2 SC 13G/A, 2 SC 13D/A, 1 SC 13G with the SEC between May 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (50)

8-K Filing — 8-K · Dec 19, 2025
Allurion Technologies Files Proxy Supplement — DEFA14A · Nov 25, 2025 Risk: low
Allurion Technologies, Inc. filed a Definitive Additional Materials proxy statement on November 25, 2025. This filing supplements previous proxy materials and i
Allurion Seeks Option Repricing, Reverse Split Amid Capital Structure Overhaul — DEF 14A · Nov 24, 2025 Risk: high
Allurion Technologies, Inc. (ALURW) is holding its annual meeting on December 18, 2025, to address several critical proposals impacting its capital structure an
Allurion's Revenue Halves, Net Loss Widens Amidst Market Headwinds — 10-Q · Nov 17, 2025 Risk: high
Allurion Technologies, Inc. reported a significant decline in financial performance for the nine months ended September 30, 2025, with revenue plummeting to $11
8-K Filing — 8-K · Nov 12, 2025
Allurion Technologies Reports Director & Officer Changes — 8-K · Oct 3, 2025 Risk: medium
Allurion Technologies, Inc. filed an 8-K on September 30, 2025, reporting changes related to its board of directors and executive compensation. The filing indic
Allurion Restates 2023 Financials, Cites Internal Control Weakness — 10-K/A · Aug 28, 2025 Risk: high
Allurion Technologies, Inc. (ALURW) filed a 10-K/A Amendment No. 2 on August 28, 2025, restating its audited consolidated financial statements for the fiscal ye
Allurion Technologies Files 10-K/A Amendment — 10-K/A · Aug 19, 2025 Risk: medium
Allurion Technologies, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ending December 31, 2024. The filing, submitted on August 19, 2
Allurion Technologies Restates Financials — 8-K · Aug 14, 2025 Risk: medium
Allurion Technologies, Inc. announced on August 14, 2025, that it will not rely on previously issued financial statements for the fiscal year ended December 31,
Allurion Technologies Files 8-K on Financials — 8-K · Aug 13, 2025 Risk: low
Allurion Technologies, Inc. filed an 8-K on August 13, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation
Allurion Technologies Files 8-K on Financials and Operations — 8-K · Aug 7, 2025 Risk: medium
Allurion Technologies, Inc. filed an 8-K on August 7, 2025, reporting events as of August 4, 2025. The filing pertains to results of operations, financial condi
Allurion Technologies Files Q1 2025 10-Q — 10-Q · May 15, 2025 Risk: medium
Allurion Technologies, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information and business operations. Key disclosur
Allurion Technologies Files 8-K on Financials — 8-K · May 14, 2025 Risk: low
Allurion Technologies, Inc. filed an 8-K on May 14, 2025, reporting on its results of operations and financial condition. The filing also includes financial sta
Allurion Technologies Files 8-K on Warrant Agreements — 8-K · Apr 17, 2025 Risk: medium
On April 15, 2025, Allurion Technologies, Inc. entered into a material definitive agreement related to warrants to purchase 1,420,455 shares of common stock at
Allurion Technologies Files 8-K on Shareholder Votes and Warrants — 8-K · Apr 10, 2025 Risk: low
Allurion Technologies, Inc. filed an 8-K on April 10, 2025, reporting on the submission of matters to a vote of security holders and financial statements. The f
Allurion Technologies Files 8-K — 8-K · Apr 3, 2025 Risk: low
Allurion Technologies, Inc. filed an 8-K on April 3, 2025, reporting on other events and financial statements. The company, incorporated in Delaware, is involve
Allurion Technologies Files 2024 10-K — 10-K · Mar 27, 2025 Risk: medium
Allurion Technologies, Inc. filed its 10-K for the fiscal year ending December 31, 2024. The company, previously known as Allurion Technologies Holdings, Inc. u
Allurion Technologies Files 8-K on Financials — 8-K · Mar 26, 2025 Risk: low
Allurion Technologies, Inc. filed an 8-K on March 26, 2025, reporting on its results of operations and financial condition. The filing also includes financial s
Allurion Technologies Files Definitive Proxy Statement — DEF 14A · Mar 24, 2025 Risk: low
Allurion Technologies, Inc. filed its definitive proxy statement (DEF 14A) on March 24, 2025, for its annual meeting on April 4, 2025. The filing concerns the c
Allurion Technologies Files 8-K on Equity Sales — 8-K · Feb 21, 2025 Risk: medium
On February 19, 2025, Allurion Technologies, Inc. entered into a material definitive agreement related to unregistered sales of equity securities. The company,
Allurion Technologies Files 8-K — 8-K · Feb 13, 2025 Risk: low
Allurion Technologies, Inc. filed an 8-K on February 13, 2025, reporting other events and financial statements. The filing details the company's principal execu
Allurion Technologies Files 8-K: Material Agreement & Equity Sale — 8-K · Jan 28, 2025 Risk: medium
On January 24, 2025, Allurion Technologies, Inc. entered into a material definitive agreement related to the unregistered sale of equity securities. The company
Allurion Technologies Files 8-K: Material Agreement, Financials — 8-K · Jan 17, 2025 Risk: medium
Allurion Technologies, Inc. announced on January 14, 2025, that it entered into a material definitive agreement. The company also reported its results of operat
Allurion Technologies S-1/A Filing Updates Share Data — S-1/A · Jan 13, 2025 Risk: medium
Allurion Technologies, Inc. filed an S-1/A on January 13, 2025, to update its registration statement. The filing includes retrospective adjustments for a busine
Allurion Technologies Files S-1/A with Financial Updates — S-1/A · Jan 8, 2025 Risk: medium
Allurion Technologies, Inc. filed an S-1/A on January 8, 2025, detailing its financial performance and business operations. The filing includes retrospective ad
Allurion Technologies Announces Board Changes and New Officer Compensation — 8-K · Jan 6, 2025 Risk: medium
Allurion Technologies, Inc. announced on December 30, 2024, the departure of Director David L. Roberts and the election of new director Dr. Jonathan M. L. Davie
Allurion Technologies Files 8-K on Security Holder Rights — 8-K · Dec 31, 2024 Risk: medium
Allurion Technologies, Inc. filed an 8-K on December 23, 2024, reporting material modifications to the rights of security holders and other events. The filing i
Allurion Technologies Files 8-K on Shareholder Vote and Financials — 8-K · Dec 18, 2024 Risk: low
Allurion Technologies, Inc. filed an 8-K on December 18, 2024, reporting on a submission of matters to a vote of security holders and financial statements. The
Allurion Technologies Files for IPO — S-1 · Dec 10, 2024 Risk: medium
Allurion Technologies, Inc. filed an S-1 form on December 10, 2024, indicating its intention to go public. The company, formerly known as Allurion Technologies
SC 13G/A Filing — SC 13G/A · Nov 14, 2024
SC 13G/A Filing — SC 13G/A · Nov 14, 2024
Allurion Technologies 10-Q: Financials and Warrants Detailed — 10-Q · Nov 13, 2024 Risk: medium
Allurion Technologies, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial position, including assets and liabil
Allurion Technologies Files Definitive Proxy Statement — DEF 14A · Nov 8, 2024 Risk: low
Allurion Technologies, Inc. filed its definitive proxy statement on November 8, 2024, for its annual meeting of stockholders on December 11, 2024. The filing, d
Allurion Technologies Files 8-K on Warrant Agreement — 8-K · Nov 4, 2024 Risk: medium
On October 30, 2024, Allurion Technologies, Inc. entered into a material definitive agreement related to warrants to purchase 14,204,555 shares of common stock
Allurion Technologies: Shareholder Nominates Director — 8-K · Oct 28, 2024 Risk: low
Allurion Technologies, Inc. filed an 8-K on October 28, 2024, reporting a shareholder nomination for its board of directors as of October 26, 2024. This filing
RTW Investments Updates Allurion Technologies Stake — SC 13D/A · Oct 24, 2024 Risk: medium
RTW Investments, LP, through an amendment filed on October 24, 2024, has updated its beneficial ownership of Allurion Technologies, Inc. The filing indicates a
Allurion Technologies Files IPO Amendment — S-1/A · Oct 3, 2024 Risk: medium
Allurion Technologies, Inc. filed an S-1/A amendment on October 3, 2024, for its initial public offering. The company, previously known as Allurion Technologies
Allurion Technologies Files S-1/A Amendment — S-1/A · Sep 30, 2024 Risk: medium
Allurion Technologies, Inc. filed an S-1/A amendment on September 30, 2024, detailing its financial status and business operations. The company, previously know
Allurion Technologies Faces Delisting Concerns — 8-K · Sep 5, 2024 Risk: high
Allurion Technologies, Inc. filed an 8-K on August 29, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule. The company is also
Allurion Technologies Appoints New Director, Reports Officer Compensation — 8-K · Sep 4, 2024 Risk: low
Allurion Technologies, Inc. filed an 8-K on September 4, 2024, reporting on the departure of Director Michael J. O'Malley and the appointment of Dr. Jonathan L.
Allurion Technologies Faces Delisting Concerns — 8-K · Aug 15, 2024 Risk: high
Allurion Technologies, Inc. filed an 8-K on August 15, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The fil
Allurion Technologies Files Q2 2024 10-Q — 10-Q · Aug 14, 2024 Risk: medium
Allurion Technologies, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported on its financial performance and operations, including deta
Allurion Technologies Files 8-K on Financials and Warrants — 8-K · Aug 13, 2024 Risk: medium
Allurion Technologies, Inc. filed an 8-K on August 13, 2024, reporting on its results of operations and financial condition, as well as financial statements and
SC 13G Filing — SC 13G · Aug 9, 2024
Allurion Technologies Prices $14.2M Stock and Warrant Offering — 8-K · Aug 7, 2024 Risk: medium
Allurion Technologies, Inc. announced on August 6, 2024, that it entered into a securities purchase agreement to sell approximately $14.2 million worth of its c
Allurion Technologies Enters Material Definitive Agreement — 8-K · Jul 5, 2024 Risk: medium
On July 5, 2024, Allurion Technologies, Inc. entered into a Material Definitive Agreement. The filing does not provide specific details about the agreement, suc
RTW Investments Updates Allurion Technologies Stake — SC 13D/A · Jul 2, 2024 Risk: medium
RTW Investments, LP, through an amendment filed on July 2, 2024, has updated its Schedule 13D/A regarding its holdings in Allurion Technologies, Inc. The filing
Allurion Technologies Files 8-K: Material Agreement & Equity Sales — 8-K · Jul 1, 2024 Risk: medium
Allurion Technologies, Inc. announced on June 28, 2024, that it entered into a material definitive agreement. The company also reported on unregistered sales of
Allurion Technologies Files 8-K with Financials — 8-K · Jun 26, 2024 Risk: low
On June 25, 2024, Allurion Technologies, Inc. filed an 8-K report detailing a Regulation FD Disclosure and Financial Statements and Exhibits. The filing include
Allurion Technologies Files S-1 — S-1 · May 31, 2024 Risk: medium
Allurion Technologies, Inc. filed an S-1 form on May 31, 2024, detailing its financial status and business operations. The company, previously known as Allurion

Risk Profile

Risk Assessment: Of ALURW's 45 recent filings, 5 were flagged as high-risk, 27 as medium-risk, and 13 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Allurion Technologies, INC.'s most recent 10-Q filing (Nov 17, 2025):

Revenue: $11.617M
Net Income: ($22.720M)
EPS: ($1.53)
Cash Position: $6.136M
Total Debt: $101.069M

Key Executives

Shantanu Gaur
Brendan M. Gibbons
Ojas Buch
Dr. Omar Ishrak
R. Jason Richey
Douglas Hudson
David L. Roberts
Dr. Jonathan M. L. Davies
Roderick Wong, M.D.
Michael J. O'Malley
Dr. Jonathan L. Weitz

Industry Context

Allurion Technologies operates in the medical device sector, specifically focusing on weight loss solutions. The industry is characterized by innovation, regulatory scrutiny from bodies like the FDA, and competition from various therapeutic approaches. Companies often rely on equity financing and strategic partnerships to fund research, development, and market expansion.

Top Tags

financials (8) · warrants (7) · governance (6) · financial-reporting (5) · sec-filing (5) · amendment (4) · equity-sale (4) · proxy-statement (3) · medical-devices (3) · 8-k (3)

Executive Compensation

From the most recent DEF 14A filing (Nov 24, 2025):

Shantanu Gaur — CEO
Ojas Buch — COO
Brendan Gibbons

Key Numbers

shares of common stock outstanding: 7,770,047 — as of the Record Date, October 31, 2025
weighted average exercise price: $57.50 — of Shantanu Gaur's 57,144 eligible options
minimum reverse stock split ratio: 1-for-1.5 — proposed for common stock
maximum reverse stock split ratio: 1-for-20 — proposed for common stock
Annual Meeting date: December 18, 2025 — when proposals will be voted on
Record Date: October 31, 2025 — for stockholders entitled to vote
Revenue: $11.617M — Decreased 56.2% from $26.519M in 2024 for the nine months ended September 30.
Net Loss: ($22.720M) — Compared to a net income of $2.410M in 2024 for the nine months ended September 30.
Cash and Cash Equivalents: $6.136M — Decreased from $15.379M at December 31, 2024, indicating significant cash burn.
Stockholders' Deficit: ($82.928M) — Worsened from ($77.978M) at December 31, 2024, reflecting accumulated losses.
Total Liabilities: $101.069M — Remains high, posing a significant financial burden for the company.
Basic Net Loss Per Share: ($1.53) — For the three months ended September 30, 2025, compared to $3.41 net income per share in 2024.
Common Shares Outstanding: 7,767,027 — As of September 30, 2025, an increase from 2,710,607 at December 31, 2024.
Aggregate market value of non-affiliate common equity: $132.3M — As of December 29, 2023, reflecting the company's valuation post-Business Combination.
Common Stock shares outstanding: 47.85M — As of March 22, 2024, after the 1-to-25 reverse stock split.

Related Companies

ALUR

Frequently Asked Questions

What are the latest SEC filings for Allurion Technologies, INC. (ALURW)?

Allurion Technologies, INC. has 50 recent SEC filings from May 2024 to Dec 2025, including 28 8-K, 4 10-Q, 4 S-1/A. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of ALURW filings?

Across 50 filings, the sentiment breakdown is: 5 bearish, 45 neutral. The dominant sentiment is neutral.

Where can I find Allurion Technologies, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Allurion Technologies, INC. (ALURW) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Allurion Technologies, INC.?

Key financial highlights from Allurion Technologies, INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for ALURW?

The investment thesis for ALURW includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Allurion Technologies, INC.?

Key executives identified across Allurion Technologies, INC.'s filings include Shantanu Gaur, Brendan M. Gibbons, Ojas Buch, Dr. Omar Ishrak, R. Jason Richey and 6 others.

What are the main risk factors for Allurion Technologies, INC. stock?

Of ALURW's 45 assessed filings, 5 were flagged high-risk, 27 medium-risk, and 13 low-risk.

What are recent predictions and forward guidance from Allurion Technologies, INC.?

Forward guidance and predictions for Allurion Technologies, INC. are extracted from SEC filings as they are enriched.